previous
develop
two
potent
chemic
class
inhibit
essenti
papainlik
proteas
plpro
sever
acut
respiratori
syndrom
coronaviru
sarscov
studi
appli
novel
approach
identifi
small
fragment
act
synergist
inhibitor
fragment
librari
screen
combin
four
previous
develop
lead
inhibitor
fluorescencebas
enzymat
assay
sever
fragment
compound
synergist
enhanc
inhibitori
activ
lead
inhibitor
approxim
order
magnitud
surfac
plasmon
reson
spr
measur
show
three
fragment
bind
specif
plpro
enzym
mode
inhibit
comput
solvent
map
molecular
dock
studi
suggest
fragment
bind
adjac
bind
site
lead
inhibitor
stabil
inhibitorbound
state
propos
potenti
next
gener
compound
base
upon
comput
fragmentmerg
approach
approach
provid
altern
strategi
lead
optim
case
direct
cocrystal
difficult
hl
perform
experi
assist
lt
jlg
kp
sc
keh
perform
comput
studi
akg
synthes
current
lead
compound
hl
sc
keh
mej
design
experi
wrote
manuscript
author
declar
compet
financi
interest
replic
plot
ligand
effici
indic
bind
free
energi
calcul
nmr
spectra
fragment
hit
compound
includ
support
inform
nih
public
access
human
sever
acut
respiratori
syndrom
coronaviru
sarscov
initi
report
guangdong
provinc
china
quickli
spread
almost
countri
result
infect
approxim
death
contain
public
health
quarantin
measur
sever
month
isol
close
relat
strain
horsesho
bat
report
suggest
potenti
reemerg
sarscov
retransmiss
human
anim
reservoir
also
three
addit
human
coronavirus
hcovemc
report
sinc
shown
less
lethal
sarscov
howev
sinc
april
fifteen
peopl
infect
recent
identifi
coronaviru
hcovemc
nine
die
pneumonia
renal
failur
whole
genom
sequenc
hcovemc
character
shown
close
similar
two
asian
bat
coronavirus
open
strong
possibl
emerg
new
strain
sar
new
sarslik
human
coronavirus
could
lead
even
deadli
outbreak
human
sarscov
posit
rna
genom
size
kb
contain
two
proteas
proteas
papainlik
proteas
plpro
plpro
respons
cleavag
polyprotein
nonstructur
protein
first
three
posit
nonstructur
protein
cleav
plpro
eleven
posit
cleav
plpro
shown
essenti
viral
replic
make
attract
drug
target
sarscov
intens
pursu
drug
target
sever
inhibitor
report
categor
coval
peptidomimet
noncoval
peptidomimet
nonpeptid
unlik
develop
plpro
inhibitor
limit
recent
despit
essenti
role
sar
viral
replic
addit
work
two
differ
type
plpro
inhibitor
report
recent
year
first
identifi
compound
screen
ic
valu
second
sever
natur
product
diarylheptanoid
isol
alnu
japonica
show
inhibitori
activ
ic
plpro
addit
primari
function
viral
peptid
cleavag
plpro
recogn
involv
deubiquitin
deisgyl
viral
evas
innat
immun
respons
sarsplpro
cystein
proteas
contain
zincbind
motif
catalyt
triad
ubiquitinlik
ntermin
domain
figur
sequenc
ident
similar
sarsplpro
hcovemc
plpro
respect
support
inform
si
figur
interestingli
predict
structur
hcovemc
plpro
similar
crystal
structur
sarsplpro
si
figur
three
catalyt
residu
four
cystein
zincbind
motif
ident
two
plpro
enzym
addit
nine
highli
conserv
residu
mani
plpro
enzym
also
observ
hcovemc
plpro
highlight
yellow
si
figur
suggest
hcovemc
plpro
may
possess
characterist
similar
sarsplpro
use
highthroughput
screen
ht
structurebas
drug
design
previous
develop
seri
noncoval
plpro
inhibitor
show
promis
potenti
therapeut
agent
inhibitor
shown
inhibitori
activ
ic
valu
antivir
activ
ec
see
tabl
inhibitor
structur
inhibitor
exhibit
inhibitori
activ
antivir
activ
respect
inhibitor
repres
two
activ
chemic
scaffold
repres
first
scaffold
repres
second
scaffold
b
four
lead
inhibitor
show
moder
antivir
activ
sarscov
potenc
must
improv
order
develop
clinic
candid
analysi
two
avail
plpro
structur
inhibitor
subsequ
molecular
model
studi
reveal
lead
inhibitor
bind
pocket
mostli
contribut
loop
side
chain
distinct
catalyt
site
shown
green
figur
inhibitor
appear
block
substrat
access
entranc
catalyt
site
plpro
enzym
scaffold
bind
similar
area
although
scaffold
inhibitor
block
littl
half
area
block
scaffold
b
inhibitor
one
way
improv
potenc
lead
inhibitor
would
optim
compound
expand
unoccupi
space
near
current
bind
site
would
requir
synthesi
larger
compound
process
consum
signific
amount
time
resourc
may
may
result
better
bind
affin
potenc
altern
strategi
applic
fragmentbas
drug
design
fbdd
methodolog
becom
wellestablish
method
lead
optim
mani
case
fbdd
use
discov
small
scaffold
optim
find
two
small
fragment
link
togeth
order
produc
potent
inhibitor
order
abl
link
two
small
fragment
solv
crystal
structur
fragment
typic
necessari
mani
case
obtain
structur
inform
challeng
timeconsum
due
typic
weak
bind
affin
fragment
target
enzym
studi
use
fbdd
combin
detail
enzymat
analysi
mean
optim
lead
inhibitor
without
use
crystallographi
test
small
librari
fragment
compound
presenc
lead
inhibitor
abl
identifi
fragment
synergist
improv
potenc
lead
inhibitor
addit
enzymat
analys
includ
mechan
inhibit
mutual
exclus
studi
describ
detail
comput
studi
use
predict
fragment
bind
locat
final
fragmentmerg
strategi
employ
predict
next
gener
compound
abl
recapitul
bind
posit
lead
inhibitor
well
key
bind
featur
identifi
fragment
two
current
develop
sarscov
plpro
inhibitor
scaffold
bind
catalyt
site
plpro
proteas
separ
nearbi
bind
site
cradl
residu
leav
catalyt
site
unoccupi
inhibit
although
catalyt
pocket
small
reason
probabl
fragment
compound
could
success
bind
locat
enhanc
inhibitori
activ
lead
inhibitor
zenobia
librari
consist
chemic
structur
divers
fragmentlik
compound
experiment
screen
presenc
four
previous
discov
lead
inhibitor
fragment
compound
test
continu
kinet
enzymat
assay
describ
method
replic
plot
inhibitor
fragment
show
highli
reproduc
result
si
figur
replic
plot
lead
inhibitor
similar
inhibitor
fragmentlik
compound
fragment
show
greater
increas
enzym
inhibit
test
fragment
concentr
presenc
inhibitor
respect
percentag
effici
indic
pei
fragment
calcul
hit
select
criteria
accord
method
abadzapatero
cowork
percent
inhibit
divid
molecular
weight
mw
compound
compound
pei
valu
greater
classifi
hit
medium
rang
pei
compound
select
test
high
pei
rang
compound
classifi
outlier
due
strong
likelihood
nonspecif
histogram
pei
valu
fragment
combin
four
lead
inhibitor
shown
si
figur
total
fragment
medium
pei
rang
select
studi
ic
valu
select
fragment
absenc
lead
inhibitor
first
determin
ic
valu
vari
fragment
fragment
summar
tabl
next
ic
valu
four
lead
inhibitor
determin
presenc
fragmentlik
compound
fragmentlik
compound
eight
fragment
show
synergist
enhanc
ic
valu
reduct
least
one
lead
inhibitor
ic
valu
inhibitor
enhanc
fragment
respect
compar
lead
inhibitor
alon
tabl
fragment
show
strongest
synergi
inhibitor
enhanc
ic
two
fragment
also
equal
enhanc
inhibitor
ic
valu
inhibitor
enhanc
respect
fragment
compound
improv
ic
valu
inhibitor
fragment
appear
better
synergi
scaffold
b
inhibitor
repres
scaffold
fragment
also
show
signific
synergist
activ
inhibitor
respect
six
eight
fragment
exhibit
revers
enzym
recoveri
two
show
recoveri
rate
respect
plpro
cystein
proteas
contain
cystein
activ
site
partial
irrevers
fragment
may
coval
interact
cystein
residu
coval
interact
compound
like
nonspecif
reactiv
usual
toxic
issu
therefor
fragment
may
good
candid
although
best
enhanc
scaffold
b
inhibitor
inhibitor
similarli
result
indic
fragment
may
also
exhibit
problem
irrevers
two
ligand
efficiencyrel
indic
bind
effici
index
bei
surfacebind
effici
index
sei
calcul
describ
bei
relat
potenc
molecular
weight
compound
sei
index
monitor
potenc
gain
polar
surfac
area
psa
increas
bei
sei
fragment
four
lead
inhibitor
calcul
simpl
equat
pic
divid
mw
bei
pic
divid
psa
sei
psa
valu
import
indic
relat
oral
bioavail
intestin
permeabl
bei
valu
fragment
suggest
outlier
due
possibl
nonspecif
interact
si
figur
fragment
contain
aldehyd
like
exhibit
nonspecif
affin
cystein
residu
catalyt
site
plpro
enzym
thu
consid
ligand
effici
indic
enzym
activ
recoveri
rate
fragment
best
enhanc
inhibitor
respect
although
observ
ic
valu
enhanc
fragment
doserespons
curv
use
enzymat
assay
possibl
result
could
due
nonspecif
interact
plpro
enzym
fragment
enzymat
assay
alon
lead
fals
posit
case
order
investig
orthogon
bind
analys
surfac
plasmon
reson
spr
perform
dissoci
equilibrium
constant
k
reflect
bind
affin
determin
four
lead
inhibitor
seven
newli
identifi
fragment
fragment
exclud
studi
due
low
ic
enhanc
bind
affin
inhibitor
vari
determin
spr
similar
rang
ic
valu
tabl
figur
promisingli
bind
affin
fragment
respect
k
fit
curv
shown
figur
exampl
howev
three
fragment
fragment
suspect
form
nonspecif
interact
due
unusu
high
bei
valu
note
spr
analys
confirm
three
fragment
well
fragment
bind
nonspecif
fragment
show
typic
doserespons
curv
concentr
increas
instead
show
random
bind
pattern
shown
figur
fragment
show
typic
doserespons
curv
spr
respons
unit
increas
almost
ru
concentr
increas
figur
like
due
multisit
bind
caus
aggreg
rather
onetoon
interact
plpro
enzym
suggest
fragment
may
bind
mani
differ
locat
plpro
enzym
mechan
inhibit
studi
thoroughli
describ
lead
inhibitor
prior
studi
suggest
inhibitor
behav
competit
inhibitor
two
crystal
structur
compound
verifi
bind
entranc
catalyt
site
block
substrat
access
site
although
lead
inhibitor
bind
directli
catalyt
site
nonetheless
display
competit
inhibit
pattern
thoroughli
investig
inhibit
mechan
lead
inhibitor
fragment
compound
kinet
studi
compound
perform
enzymeinhibitor
complex
vari
substrat
concentr
data
fit
four
equat
equat
method
three
plot
michaelismenton
lineweaverburk
dixon
use
sigmaplot
enzym
kinet
modul
akaik
inform
criterion
correct
aicc
valu
use
determin
best
fit
equat
lowest
aicc
valu
correspond
best
fit
equat
order
abl
determin
equat
fit
best
aicc
valu
differ
least
unit
next
lowest
four
previous
develop
lead
inhibitor
show
noncompetit
inhibit
unequ
bind
affin
free
enzym
e
substratebound
enzym
es
alpha
valu
equal
tabl
four
lead
inhibitor
show
valu
greater
indic
bind
affin
free
enzym
tighter
es
dixon
plot
noncompetit
inhibit
inhibitor
respect
substrat
shown
figur
result
k
valu
three
fragment
show
noncompetit
inhibit
differ
valu
well
fragment
valu
greater
indic
fragment
also
behav
similar
lead
inhibitor
although
valu
fragment
smaller
lead
inhibitor
may
explain
display
strongest
effect
three
lead
inhibitor
fragment
exhibit
strongest
synergist
effect
scaffold
b
inhibitor
dixon
plot
noncompetit
inhibit
fragment
shown
figur
k
valu
determin
four
lead
inhibitor
two
fragment
show
noncompetit
inhibit
valu
greater
like
compound
bind
anoth
site
catalyt
site
hinder
substrat
bind
enzym
studi
therefor
suggest
unlik
newli
identifi
fragmentlik
compound
bind
catalyt
site
plpro
enzym
mechan
inhibit
bind
synergymutu
exclus
analys
determin
newli
identifi
fragmentlik
compound
bind
site
separ
lead
inhibitor
unfortun
inform
insuffici
identifi
fragment
bind
plpro
enzym
therefor
investig
possibl
bind
site
candid
unexplor
catalyt
pocket
design
candid
fragment
bind
site
although
mechan
inhibit
studi
indic
locat
like
fragment
bind
site
identifi
addit
candid
fragment
bind
site
perform
seri
comput
solvent
map
experi
hot
spot
analys
use
ftmap
server
see
method
ftmap
multistag
protein
map
algorithm
base
fast
fourier
transform
fft
correl
approach
effici
search
potenti
bind
site
entir
surfac
protein
two
model
system
crystal
structur
inhibitor
bound
plpro
pdb
id
inhibitor
bound
plpro
pdb
id
use
analys
two
provid
repres
crystal
structur
compound
scaffold
use
total
nanosecond
molecular
dynam
md
simul
system
determin
major
fluctuat
structur
come
zinc
bind
motif
beta
sheet
form
catalyt
triad
repres
snapshot
structur
extract
simul
discuss
see
method
submit
ftmap
server
perform
fragmentbas
bind
site
analysi
two
strong
candid
fragment
bind
site
identifi
analyz
origin
structur
consensu
cluster
probe
molecul
use
see
method
two
hot
spot
identifi
analysi
includ
extens
origin
bind
site
lead
inhibitor
one
caviti
palm
region
shown
figur
hot
spot
larger
lead
inhibitor
bind
site
includ
addit
caviti
unoccupi
lead
inhibitor
bind
site
previous
discuss
possibl
substrat
recognit
site
extend
caviti
compos
five
residu
second
posit
identifi
ftmap
hot
spot
locat
away
lead
inhibitor
bind
site
catalyt
site
plpro
encompass
zincbind
motif
palm
region
lastli
small
volum
contain
catalyt
triad
site
identifi
ftmap
like
due
smaller
size
pocket
structur
analysi
comput
studi
identifi
four
potenti
fragment
bind
site
three
locat
within
bind
site
lead
inhibitor
candid
bind
site
shown
green
unoccupi
catalyt
pocket
figur
identifi
analysi
cocryst
structur
avail
candid
bind
site
identifi
ftmap
use
comput
solvent
map
discuss
method
surround
residu
candid
bind
site
locat
right
lead
inhibitor
bind
site
figur
shown
blue
addit
coars
dock
studi
hit
fragment
compound
see
method
identifi
anoth
shallow
bind
site
design
candid
bind
site
shown
orang
figur
mechan
inhibit
analys
mutual
exclus
studi
discuss
indic
fragment
bind
combin
lead
inhibitor
distinct
separ
bind
site
enzym
import
observ
lay
foundat
futur
fragmentinhibitor
merg
link
studi
propos
order
investig
candid
fragment
bind
site
predict
like
bind
conform
fragment
within
site
perform
seri
comput
bind
free
energi
calcul
studi
describ
detail
method
use
combin
molecular
dock
molecular
simul
molecular
mechanicspoissonboltzmann
surfac
area
mmpbsa
calcul
predict
bind
free
energi
bind
lead
inhibitor
synergist
fragment
place
adjac
candid
bind
site
studi
perform
use
three
potenti
bind
site
site
catalyt
site
site
extend
lead
inhibitor
bind
site
site
identifi
coars
dock
hot
spot
exclud
studi
due
larg
distanc
inhibitor
bind
site
hot
spot
shallow
highli
solvent
expos
locat
zincbind
motif
palm
region
see
figur
importantli
appear
like
even
bind
small
fragment
posit
could
caus
degre
conform
chang
two
region
structur
chang
would
like
affect
lead
inhibitor
bind
site
enhanc
ic
valu
extent
observ
reason
well
impract
fragmentlink
merg
strategi
distanc
hot
spot
exclud
analys
calcul
free
energi
bind
lead
inhibitor
fragment
place
success
candid
site
compar
experiment
determin
bind
affin
ic
lead
inhibitor
synergist
fragment
predict
like
fragment
bind
site
purpos
studi
bind
conform
inhibitor
cocryst
structur
repres
scaffold
b
util
fragment
select
use
studi
due
strong
synergist
effect
inhibitor
fragment
dock
three
candid
bind
site
discuss
three
dock
pose
fragment
select
simul
see
method
post
analysi
simul
result
mmpbsa
allow
calcul
bind
free
energi
lead
inhibitor
simul
shown
figur
initi
note
fragment
stabl
bind
site
repeatedli
drift
site
nanosecond
mark
regardless
start
posit
suggest
shallow
solvent
expos
bind
site
also
appropri
posit
fragment
bind
henc
site
also
remov
consider
analysi
site
perform
addit
analysi
mmpbsa
result
figur
si
tabl
reveal
catalyt
site
site
also
favor
posit
fragment
bind
bind
free
energi
valu
inhibitor
fragment
posit
higher
calcul
inhibitor
alon
well
experiment
deriv
result
result
taken
togeth
experiment
result
discuss
indic
catalyt
site
like
bind
site
identifi
synergist
fragment
favor
result
close
align
experiment
valu
obtain
howev
fragment
place
bind
site
shown
figur
consist
synergist
activ
note
prefer
posit
charg
seen
piperazin
amin
group
place
anion
pocket
site
defin
combin
establish
bind
featur
lead
inhibitor
result
clear
gain
calcul
bind
affin
addit
edgetofac
pi
stack
interact
naphthalen
ring
system
aromat
ring
system
fragment
visibl
figur
may
stabil
lead
inhibitor
bind
conform
order
priorit
compound
candid
futur
synthesi
test
undertaken
seri
fragmentmerg
dock
analys
util
inform
determin
bind
site
predict
studi
discuss
fragmentmerg
strategi
involv
elimin
potenti
problemat
nitroaromat
ring
fragment
direct
incorpor
piperazin
ring
lead
inhibitor
scaffold
shown
figur
seri
propos
compound
design
use
varieti
link
group
posit
discuss
method
dock
extend
bind
site
defin
lead
inhibitor
bind
site
tabl
propos
compound
select
score
abil
success
recapitul
key
bind
featur
inhibitor
synergist
fragment
includ
lipophil
interact
naphthalen
ring
system
posit
posit
charg
amin
piperazin
key
anion
pocket
discuss
attempt
improv
potenc
current
develop
lead
plpro
inhibitor
fragmentlik
librari
enzymat
test
combin
four
lead
inhibitor
discov
total
eight
fragmentlik
compound
synergist
enhanc
inhibitori
activ
lead
inhibitor
orthogon
bind
analysi
spr
confirm
bind
three
fragment
also
determin
direct
bind
affin
k
character
assay
bind
mechan
two
newli
identifi
fragment
compound
show
noncompetit
inhibit
indic
synergist
fragment
compound
bind
catalyt
site
plpro
enzym
comput
analysi
predict
sever
potenti
fragment
bind
site
expans
studi
reveal
prefer
fragment
bind
site
extens
lead
inhibitor
bind
site
inhibitor
bind
site
occupi
repres
structur
enzymat
character
comput
studi
suggest
fragment
bind
adjac
bind
site
lead
inhibitor
abl
stabil
inhibitorbound
state
use
structur
inform
reveal
studi
abl
appli
fragmentmerg
strategi
suggest
sever
next
gener
compound
high
predict
bind
affin
novel
approach
describ
may
prove
benefici
case
direct
crystal
studi
prove
difficult
zenobia
librari
consist
structur
divers
small
fragmentlik
compound
purchas
zenobia
therapeut
molecular
weight
compound
vari
da
da
mean
molecular
weight
da
mean
number
hbond
donor
acceptor
respect
mean
clogp
topolog
polar
surfac
area
tpsa
valu
respect
solubl
compound
verifi
vendor
least
mm
dmso
compound
zenobia
librari
function
chemic
divers
synthet
access
optim
categor
distribut
shape
divers
mixtur
compound
plate
column
four
lead
inhibitor
provid
dr
ghosh
plpro
substrat
zargleuargglyglyamc
purchas
bachem
bioscienc
previous
develop
inhibitor
synthes
dr
ghosh
puriti
compound
confirm
nmr
describ
fragment
repurchas
sigma
compound
puriti
determin
nmr
nmr
spectra
fragment
compound
list
tabl
includ
support
inform
plpro
gene
sarscov
polyprotein
residu
human
rhinoviru
proteas
cleavag
site
tag
levlfqgphhhhhh
cterminu
initi
prepar
codonoptim
gene
synthesi
biobas
inc
clone
vector
ncoi
xhoi
stop
codon
ad
immedi
last
plpro
gene
gener
nativ
plpro
without
tag
l
cell
novagen
contain
recombin
plasmid
grown
od
shake
rpm
lb
medium
contain
ampicillin
chloramphenicol
ml
nativ
plpro
express
ad
mm
iptg
incub
continu
h
cell
harvest
centrifug
rpm
beckman
minut
resuspend
lysi
buffer
lysozym
proteas
inhibitor
cocktail
buffer
mm
trishcl
ph
mm
bme
sonic
ice
lysat
centrifug
rpm
beckman
min
supernat
collect
supernat
subject
ammonium
sulfat
fraction
suspens
centrifug
result
pellet
resuspend
buffer
b
ammonium
sulfat
mm
tri
ph
mm
bme
centrifug
remov
precipit
supernat
load
onto
ml
phenylsepharos
fastflow
hs
column
amersham
bioscienc
piscataway
nj
equilibr
buffer
b
ammonium
sulfat
mm
tri
ph
mm
bme
protein
elut
stepwis
gradient
buffer
nativ
plpro
elut
buffer
fraction
contain
plpro
pool
dialyz
buffer
overnight
load
onto
hitrap
qxl
amersham
bioscienc
protein
elut
stepwis
gradient
buffer
c
mm
tri
ph
nacl
mm
bbme
plpro
elut
buffer
c
pure
sarscov
plpro
fraction
combin
bufferexchang
buffer
contain
glycerol
store
puriti
determin
sdspage
analysi
zenobia
librari
purchas
mm
dmso
stock
compound
experiment
test
plpro
combin
four
previous
develop
plpro
inhibitor
plpro
activ
measur
continu
kinet
assay
ubiqutinderiv
substrat
zargleuargglyglyamc
bachem
bioscienc
gener
fluoresc
signal
excit
nm
emiss
nm
aminomethylcoumarin
amc
cleav
primari
screen
zenobia
compound
first
dilut
mm
dmso
stock
plate
corn
inc
mm
origin
compound
solut
assay
buffer
contain
mm
hepe
ph
triton
mgml
bsa
mm
gsh
distribut
black
low
volum
plate
corn
inc
mm
zenobia
compound
ad
assay
buffer
plpro
enzym
solut
nm
final
concentr
prepar
presenc
four
lead
inhibitor
concentr
equal
ic
valu
plpro
absenc
inhibitor
also
prepar
control
enzymelead
inhibitor
mixtur
solut
ad
plate
contain
zenobia
compound
plate
incub
addit
minut
reaction
initi
ad
substrat
final
concentr
fluoresc
intens
continu
monitor
polarstar
optima
micropl
reader
bmg
labtech
minut
compound
test
duplic
plate
contain
total
posit
neg
control
ic
valu
fragment
compound
show
synergist
inhibitori
activ
determin
seri
differ
concentr
hit
compound
prepar
ic
valu
four
lead
inhibitor
measur
concentr
enzym
substrat
initi
screen
seri
lead
compound
concentr
absenc
presenc
hit
compound
reaction
initi
ad
fluorogen
substrat
activ
continu
monitor
ic
valu
calcul
fit
threeparamet
hill
equat
originpro
originlab
inc
percent
inhibit
x
inhibitor
concentr
n
slope
concentrationrespons
curv
hill
slope
vmax
maxim
inhibit
three
independ
assay
revers
hit
fragment
compound
determin
dilut
method
plpro
enzym
prepar
nm
solut
assay
concentr
incub
screen
compound
ic
concentr
minut
room
temperatur
assay
buffer
contain
mm
hepe
ph
mm
gsh
triton
mgml
bsa
dmso
final
volum
plpro
amount
dmso
place
fragment
compound
also
prepar
way
control
activ
plpro
measur
way
ic
measur
enzymeinhibitor
solut
dilut
incub
minut
measur
recoveri
enzym
activ
revers
assay
done
triplic
untag
nativ
plpro
enzym
prepar
pb
mm
phosphat
ph
mm
kcl
mm
nacl
immobil
sensor
chip
use
standard
aminecoupl
c
run
buffer
hbsp
mm
hepe
mm
nacl
surfact
ge
healthcar
use
biacor
instrument
flow
channel
activ
carbodiimid
hydrocholorid
edc
nhydroxi
succinimid
nh
mixtur
activ
surfac
block
ethanolamin
ph
control
plpro
enzym
dilut
mm
sodium
acet
ph
immobil
flow
channel
sensor
surfac
activ
edc
nh
min
inject
follow
ethanolamin
block
unoccupi
surfac
area
plpro
immobil
level
flow
channel
ru
ru
respect
four
previous
discov
inhibitor
seven
identifi
zenobia
fragment
compound
prepar
mm
inhibitor
mm
fragment
dmso
stock
compound
solut
seri
increas
concentr
inhibitor
fragment
dilut
appli
four
channel
flow
rate
sensorgram
analyz
use
biaevalu
softwar
respons
unit
differ
valu
concentr
measur
bind
equilibr
phase
sigmaplot
use
fit
data
singl
rectangular
hyperbol
curv
determin
k
valu
hyperbola
function
k
x
use
plot
respons
unit
correspond
concentr
respons
ymax
maximum
respons
compound
concentr
plpro
activ
monitor
way
primari
screen
vari
concentr
inhibitor
compound
substrat
concentr
compound
vari
least
ic
valu
fragment
data
fit
follow
equat
use
sigmaplot
enzym
kinet
modul
order
determin
best
fit
inhibit
mechan
kinet
paramet
compound
v
reaction
rate
v
max
maximum
rate
reaction
k
michaelismenten
constant
substrat
substrat
concentr
inhibitor
concentr
k
dissoci
constant
inhibitor
free
enzym
dissoci
constant
inhibitor
es
complex
fragment
bind
site
analysisal
molecular
dynam
simul
perform
use
amber
suit
program
amber
two
known
cocryst
structur
inhibitorbound
pdb
obtain
rcsb
protein
data
bank
multim
protein
complex
reduc
function
monom
form
simul
bound
inhibitor
zinc
ion
retain
system
ion
crystal
water
remov
ligand
paramet
gener
use
antechamb
softwar
ambertool
gener
amber
forc
field
gaff
charg
leap
use
neutral
system
ad
sodium
ion
system
solvat
use
water
rectangular
box
system
prepar
use
forc
field
minim
use
sander
carri
two
step
first
water
molecul
minim
step
keep
protein
fix
second
entir
system
minim
addit
step
period
boundari
condit
appli
nonbond
cutoff
system
heat
k
k
use
nvt
ensembl
ps
posit
restraint
protein
follow
system
equilibr
ps
use
npt
ensembl
without
restraint
product
phase
simul
perform
use
npt
ensembl
without
posit
restraint
ns
postanalysi
perform
use
ptraj
modul
ambertool
comput
averag
structur
everi
ns
write
pdb
file
averag
coordin
total
snapshot
extract
use
method
pdb
file
gener
upload
ftmap
server
http
ftmapbuedu
ftmap
server
remov
water
ion
bound
ligand
retain
protein
structur
sixteen
differ
probe
use
ethanol
isopropanol
isobutanol
aceton
acetaldehyd
dimethyl
ether
cyclohexan
ethan
acetonitril
urea
methylamin
phenol
benzaldehyd
benzen
acetamid
n
ndimethylformamid
output
result
gener
ftmap
form
pdb
file
consensu
cluster
differ
probe
map
surfac
plpro
structur
cluster
site
identifi
ftmap
requir
conserv
among
molecular
probe
select
studi
describ
two
site
identifi
see
discuss
one
addit
candid
bind
site
site
identifi
use
coars
dock
studi
describ
bind
affin
predictionsto
investig
potenti
bind
site
fragment
dock
enzym
use
glidexp
extra
precis
induc
fit
dock
ifd
protocol
use
default
set
structur
plpro
bound
pdb
id
pdb
id
obtain
rcsb
protein
data
bank
pdb
prior
molecular
dock
structur
protein
target
prepar
use
protein
prepar
wizard
softwar
packag
suit
water
molecul
crystal
structur
remov
crystal
multim
reduc
monom
residu
locat
within
bound
inhibitor
refin
prime
algorithm
two
distinct
dock
run
perform
use
strategi
first
dock
run
blind
dock
coars
dock
dock
area
defin
within
lead
inhibitor
candid
site
identifi
studi
highscor
bind
site
multipl
fragment
subsequ
dock
run
defin
locat
candid
site
identifi
structur
comput
analys
describ
bind
site
catalyt
site
defin
select
residu
bind
site
defin
select
residu
bind
site
defin
select
residu
bind
hot
spot
studi
reason
describ
case
dock
area
defin
box
center
select
residu
fragment
zenobia
librari
prepar
multipl
tautom
proton
state
ph
ligprep
eight
activ
fragment
dock
coars
dock
studi
fragment
dock
subsequ
candid
site
dock
studi
dock
pose
rank
glide
xp
score
second
dock
run
three
conform
pose
bind
site
site
produc
ifd
select
start
conform
md
simul
subsequ
mmpbsa
calcul
describ
bind
pose
select
includ
top
score
pose
two
pose
possess
greatest
differ
calcul
rmsd
md
simul
subsequ
mmpbsa
calcul
use
predict
bind
affin
perform
use
amber
suit
program
amber
prepar
md
simul
includ
parameter
fragment
inhibitor
prepar
equilibr
system
perform
exactli
describ
bind
site
analys
product
phase
simul
perform
use
npt
ensembl
without
posit
restraint
nanosecond
python
script
mmpbsapi
includ
use
perform
mmpbsa
calcul
first
frame
last
nanosecond
equilibr
simul
trajectori
file
use
mmpbsa
calcul
ionic
strength
molar
set
intern
dielectr
constant
set
default
option
set
default
set
valu
free
energi
bind
inhibitor
combin
three
differ
fragment
pose
calcul
accord
follow
equat
g
complex
calcul
gibb
free
energi
inhibitorfragmentenzym
complex
g
receptor
gibb
free
energi
fragmentenzym
complex
g
ligand
gibb
free
energi
calcul
inhibitor
compound
free
energi
valu
term
estim
sum
four
term
e
mm
molecular
mechan
energi
molecul
express
sum
intern
energi
molecul
plu
electrostat
van
der
waal
interact
gpsolv
polar
contribut
solvat
energi
molecul
gnpsolv
nonpolar
solvat
energi
absolut
temperatur
vibrat
rotat
translat
entropi
molecul
estim
normal
mode
analysi
use
regularli
space
snapshot
first
frame
last
nanosecond
md
simul
ionic
strength
normal
mode
calcul
set
fragment
merg
dockinga
fragment
merg
strategi
employ
base
bind
conform
observ
mmpbsa
studi
figur
propos
compound
design
merg
structur
lead
inhibitor
fragment
nitroaromat
ring
delet
remain
piperazin
ring
attach
sever
differ
site
lead
inhibitor
use
varieti
differ
link
group
goal
retain
lead
bind
posit
inhibitor
scaffold
dock
merg
hybrid
investig
sever
altern
link
strategi
includ
link
naphthalen
ring
chiral
methyl
group
ptoluidin
scaffold
methylenedioxybenzen
scaffold
b
alkyl
group
ester
group
amid
group
bind
conform
virtual
gener
hybrid
collect
predict
use
glide
dock
sp
score
structur
plpro
bound
pdb
id
pdb
id
use
dock
studi
prepar
use
protein
prepar
softwar
describ
dock
site
defin
box
center
origin
bind
site
lead
inhibitor
hybrid
compound
librari
prepar
describ
fragment
inhibitor
dock
propos
compound
discuss
select
score
visual
comparison
crystallograph
posit
lead
inhibitor
predict
bind
conform
fragment
refer
web
version
pubm
central
supplementari
materi
work
support
nation
institut
health
grant
work
use
extrem
scienc
engin
discoveri
environ
xsede
support
nation
scienc
foundat
grant
number
keh
support
portion
work
nidcr
uic
colleg
dentistri
program
molecular
graphic
imag
produc
use
ucsf
chimera
packag
resourc
biocomput
visual
informat
univers
california
san
francisco
support
nih
thank
chemaxon
ltd
academ
research
licens
cheminformat
suit
includ
jchem
jchem
excel
data
analysi
sever
acut
respiratori
syndrom
plpro
papainlik
proteas
shown
two
potenti
bind
site
identifi
ftmap
use
cocryst
structur
plpro
inhibitor
first
candid
site
upper
circl
extens
lead
inhibitor
bind
site
form
grey
orang
blue
green
pink
second
candid
site
lower
circl
encompass
zincbind
motif
palm
region
b
unoccupi
catalyt
pocket
surround
three
residu
small
pocket
initi
consid
potenti
fragment
bind
site
subsequ
elimin
c
two
small
unoccupi
pocket
near
plpro
lead
inhibitor
bind
site
bind
site
identifi
ftmap
calcul
bind
free
energi
inhibitor
fragment
dock
differ
candid
site
three
differ
dock
conform
circl
triangl
squar
bind
site
select
calcul
neg
number
repres
better
bind
conform
one
mark
black
arrow
best
one
probabl
bind
conform
fragment
orang
combin
lead
inhibitor
magenta
magenta
b
residu
plpro
enzym
interact
fragment
shown
box
right
hydrogen
bond
shown
green
propos
compound
green
carbon
molecular
dock
abl
recapitul
crystallograph
posit
inhibitor
predict
posit
synergist
fragment
orang
carbon
potenti
problemat
nitroaromat
ring
fragment
remov
favor
merg
compound
directli
incorpor
piperazin
ring
lead
inhibitor
scaffold
key
bind
featur
inhibitor
synergist
fragment
conserv
includ
lipophil
interact
naphthalen
ring
system
posit
posit
charg
amin
piperazin
key
anion
pocket
chemic
structur
highlight
lead
inhibitor
moieti
highlight
grey
circl
came
fragment
linker
lead
inhibitor
fragment
part
highlight
small
oval
